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Abstract
To evaluate the long-term effect of breast conservation with accelerated partial breast irradiation (APBI) for early-stage
breast cancer, PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database,
Chinese Scientific Journals Full-text Database, and China Journal Full-text Database were searched to identify relevant
original published trials. Randomized controlled trials in any language comparing APBI with whole-breast radiotherapy
in patientswith early-stagebreast cancerwere included.RevMan5 softwarewasused for statistical analysis. Four trials
involving 919 patients were included. The rate of 5- and 7-year excellent/good cosmetic results was significant {odds
ratio (OR) = 2.09 [95% confidence interval (CI) = 1.21-3.62]} between two groups. The 5- and 8-year overall survival
had no significant difference [OR = 1.76 (95% CI = 0.67-4.62) and OR = 0.86 (95% CI = 0.44-1.66)]. The 10-year
overall survival had significant differences [OR = 0.56 (95% CI = 0.35-0.91)]. There were no differences in the 5-year
local recurrence (LR)–free survival [OR = 0.65 (95% CI = 0.18-2.34)], cancer-specific survival [OR = 1.67 (95% CI =
0.39-7.12)], disease-free survival [OR = 0.84 (95% CI = 0.38-1.84)], LR [OR = 1.36 (95% CI = 0.46-3.99)], the rate of
contralateral breast cancer [OR = 2.82 (95% CI = 0.73-10.89)], and distant metastasis [OR = 0.71 (95% CI = 0.22-
2.31)]. APBI significantly improved the rate of excellent/good cosmetic results anywhere in the breast, shortened the
treatment time, alleviated the pain, and improved the quality of life. Future large-scale, high-quality, and double-blind
trials are needed.
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Introduction
Breast-conserving surgery (BCS) and radiotherapy of the conserved
breast have become widely accepted for the treatment of early-stage
breast cancer. The main advantage of breast-conserving therapy is the
excellent cosmetic outcome with less psychologic trauma compared
with mastectomy. BCS followed by adjuvant to the whole-breast
radiotherapy (WBRT) is the standard treatment for early-stage breast
cancer in United Kingdom now. At the present, the standard WBRT
technique after BCS is to treat the whole breast up to a total dose of 45
to 50 Gy, with or without a tumor bed boost [1–3]. However, about
one third of women will develop acute skin toxicity after whole-breast
irradiation for the high occurrence of acute moist dermatitis and the
incidence of edema and hype pigmentation.
Many clinical trials have shown that breast intensity-modulated
radiotherapy (IMRT) is a new technique. The use of IMRT for the
treatment of the whole breast yields a significant decrease of the occur-
rence of acute moist dermatitis and the incidence of edema and hype
pigmentation compared with WBRT, improves the quality of the life,
reduces psychologic burden, and improves cosmetic effect [4–7].
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However, the major disadvantage of standard WBRT or IMRT is
that it usually needs about 5 to 7 weeks. In other series, 15% to 30%
of women treated with BCS failed to receive radiation therapy (RT)
[8–10]. The reasons for the underuse of this treatment include patient
convenience, physician preference, and logistical problems [10,11].
Accelerated partial breast irradiation (APBI) is an attractive treatment
that needs only 1 to 2 weeks. The acceleration of RT would eliminate
some of the disadvantages of the extended treatment period, especially
for elderly patients. In addition, most local recurrences (LRs) occur
in close proximity to the tumor bed [12,13].
We conducted a meta-analysis to assess the effect of APBI in
patients with early-stage breast cancer after BCS.
Methods
Inclusion and Exclusion Criteria
All randomized controlled trials (RCTs), published and unpub-
lished, were eligible for this meta-analysis. All the trials that com-
pared APBI versus conventional WBRT in patients with early-stage
breast cancer were eligible. The control group received WBRT; the
treatment group received APBI. Planned conventional radiotherapy
was 40 to 60 Gy for 5 to 6 weeks. Primary outcomes were response
rate of excellent/good cosmetic results, the 5- and 8-year overall survival,
the 10-year overall survival, the 5-year LR-free survival, cancer-specific
survival, disease-free survival, LR, the rate of contralateral breast cancer
and distant metastasis.
Literature Search
PubMed (1966-June 2013), Cochrane Library (Issue 3, 2008),
EMBASE (1974-June 2013), Web of Science (1974-June 2013),
Chinese Biomedical Literature Database (1978-June 2013), Chinese
Scientific Journals Full-text Database (1989-June 2013), and China
Journal Full-text Database (1997-June 2013) were independently
searched in duplicate to identify all published (manuscripts and
abstracts) RCTs that compared APBI versus conventional WBRT in
patients with early-stage breast cancer. Manual searches were done by
reviewing articles and abstracts cited in the reference lists of identified
RCTs. In addition, abstracts published in the Proceedings of the
Annual Meetings of the American Society of Clinical Oncology
(through 2012) were systematically searched for evidence relevant to
this meta-analysis. There were no language and date restrictions.
The following search terms were used: 1) breast neoplasm, breast
tumor, human mammary carcinoma, human mammary neoplasm,
and breast cancer; 2) accelerated partial breast irradiation; 3) seg-
mental mastectomy, partial mastectomy, limited resection mastectomy,
lumpectomy, local excision mastectomy, and breast-conserving surgery;
and 3) clinical trial phase III and randomized controlled trials. The
searches were done by integrating Mesh heading [MEDLINE (Mesh),
EMBASE (EMTREE)] and with text words. All the searched abstracts
were screened for relevance. The selection of studies for inclusion was
carried out independently by two individuals.
Data Extraction and Quality Assessment
Data was extracted by Ye and Bao. The results were compared, and
disagreements were resolved by consensus. Each study was evaluated
for quality by two reviewers using the following Quality Assess Criteria
of RCT: 1) randomized method, 2) allocation concealment, 3) blind-
ness to whether it was adapted, and 4) with or without lost follow-up
(if it has been lost to follow-up, whether with analysis in intention
to treat) [14]. If only one criterion was satisfied, the bias of trials was
moderate. If none of the criteria was satisfied, the bias was severe. In
addition, we analyzed the baseline information and status of patients to
judge the practice bias. If reviewers disagreed with the quality assess-
ment, discrepancies were identified, and a consensus was reached.
Data Analysis and Statistical Methods
We analyzed, extracted, and pooled data using Review Manager 5.0
(The Nordic Cochrane Centre, Copenhagen, Denmark) for sum-
mary estimate [15]. Dichotomous outcomes of standard mean were
expressed as risk ratios with 95% confidence intervals (CIs). The
w2 statistic was used to assess heterogeneity between trials, and
Figure 1. Flow chart of the studies.
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the I2 statistic was used to assess the extent of inconsistency [16]. A
fixed-effect model was used for calculations of summary estimates
and their 95% CI, unless there was significant heterogeneity, in
which case results were confirmed using a random-effects statistical
model. Sensitivity analysis was performed by excluding the trials in
which quality was very poor or there existed a significant clinical
heterogeneity. Publication bias is a common concern in meta-analysis
that is related to the tendency of journals to favor the publication of
large and positive studies.
Results
We obtained 319 potentially eligible publications after six articles
were excluded when reading title and abstract, for these six articles
were irrelevant with our study. Figure 1 showed the flow chart of the
studies. Four RCTs [17–20] with 919 patients were used for
this meta-analysis.
Table 1 showed the characteristics of patients and treatment in the
included trials [17–20]. APBI modalities varied between the trials in
terms of study, sample, outcome indexes, as well as quality assessment.
Thus, there were no significant differences in main characteristics
between groups.
Methodological Quality of Included Studies
The specific information on study design was shown in Table 2
[17–20]. Each included RCT as assessed for quality using the vali-
dated quality assessment criteria of RCT [15]. Only one [17] of
the four studies pointed out that randomization was done with
computer-generated method and used a single-blind trial and de-
scribed the allocation concealment. One study did not describe the
randomization. Two studies are clinical trials; the allocation
concealment of the three trials was unclear.
Meta-Analysis
Overall survival. Three trials [17,19,20] reported the 5-, 8-, and
10-year overall survival rate. There were no differences statistically
between APBI and WBRT in 5-year overall survival rate [odds ratio
(OR) = 1.76 (95% CI = 0.67-4.62), P = .25] and 8-year overall sur-
vival rate [OR = 0.86 (95% CI = 0.44-1.66), P = .65], but there
was statistical difference in 10-year overall survival rate [OR = 0.56
(95% CI = 0.35-0.91), P = .02] (Figure 2).
LR-free survival. Two trials [17,18] reported the 5- and 7-year
LR-free survival rate. There were no differences between APBI and
WBRT in 5-year LR-free survival rate [OR = 0.65 (95% CI =
0.18-2.34), P = .51] and 7-year LR-free survival rate [OR = 1.33
(95% CI = 0.49-3.62), P = .57] (Figure 3).
Cancer-specific survival. Three trials [17–19] reported the 5-, 7-,
and 10-year cancer-specific survival rate. There were no differences
between APBI and WBRT in 5-year cancer-specific survival rate
[OR = 1.67 (95% CI = 0.39-7.12), P = .49], 7-year cancer-specific
survival rate [OR = 1.40 (95% CI = 0.29-6.65), P = .67], and 10-year
cancer-specific survival rate [OR = 1.43 (95% CI = 0.62-3.30),
P = .40] (Figure 4).
Disease-free survival. Two trials [17,19] reported the 5- and
10-year disease-free survival rate. There were no differences between
APBI and WBRT in 5-year disease-free survival rate [OR = 0.84Ta
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(95% CI = 0.38-1.84), P = .66], but there was difference in 10-year
disease-free survival rate [OR = 0.63 (95% CI = 0.41-0.99), P = .04]
(Figure 5).
The rate of excellent/good cosmetic results. Two trials [17,18]
reported the 5- and 7-year excellent/good cosmetic rate. There were
differences between APBI and WBRT in 5-year excellent/good
cosmetic rate [OR = 2.09 (95% CI = 1.21-3.62), P = .009] and 7-year
excellent/good cosmetic rate [OR = 3.42 (95% CI = 1.25-9.38),
P = .02] (Figure 6).
LR rate. Two trials [17,18] reported the 5-year LR rate. There
were no differences between APBI and WBRT in 5-year LR rate
[OR = 1.36 (95% CI = 0.46-3.99), P = .58]. Tests for heterogeneity
in the analysis were not statistically significant (P = .70). Two trials
[19,20] reported the 8- and 10-year LR rate. There were no differences
between APBI and WBRT in 8-year LR rate [OR = 2.91 (95%
CI = 0.87-9.65), P = .08] and in 10-year LR rate [OR = 1.26 (95%
CI = 0.49-3.27), P = .63] (Figure 7).
The contralateral breast cancer rate. Three trials [17–19] reported
the 5-, 7-, and 10-year contralateral breast cancer rate. There were
no differences between APBI and WBRT in 5-year contralateral breast
cancer rate [OR = 2.82 (95% CI = 0.73-10.89), P = .13], in 7-year
contralateral breast cancer rate [OR = 0.19 (95% CI = 0.01-4.00),
P = .28], and in 10-year contralateral breast cancer rate [OR = 0.48
(95% CI = 0.20-1.15), P = .10] (Figure 8).
Distant metastasis rate. Two trials [17,19] reported the 5- and
10-year distant metastasis rate. There were no differences between
APBI and WBRT in 5-year distant metastasis rate [OR = 0.71 (95%
CI = 0.22-2.31), P = .57] and in 10-year distant metastasis rate [OR =
0.53 (95% CI = 0.24-1.18), P = .12] (Figure 9).
The grade 2 or worse late radiation side effects. One trial [18]
reported the 7-year grade 2 or worse late radiation side effects. There
were no differences between APBI and WBRT in 7-year grade 2 or
worse late radiation side effects [OR = 0.47 (95% CI = 0.08-2.68),
Table 2. Quality Assessment of Randomized Controlled Trials Included in this Meta-Analysis.
Study (year) Randomization Allocated Concealment Blinding Loss of Follow-up Selective Outcome Reporting Other Potential Threats to Validity
Dodwell DJ et al. (2005) Unclear Unclear Unclear No Unclear Unclear
Polgár C et al. (2007) Compute Adequate Single-blind No Unclear Unclear
Antonucci JV et al. (2009) Unclear Unclear Unclear No Unclear Unclear
Major T. et al. (2004) Unclear Unclear Unclear No Unclear Unclear
Figure 2. The 5-, 8-, and 10-year overall survival.
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P = .39] and in 7-year incidence of grades 2 to 3 fibrosis rate [OR =
3.42 (95% CI = 0.86-13.60), P = .08] (Figure 10).
Discussion
This meta-analysis showed the benefit of the APBI, but no subgroups
have been able to unequivocally identify the use of ABPI that can be
regarded as a safe and standard alternative to WBRT [21].
WBRT remains the golden standard for patients with BCS, but the
rate of moist desquamation varies highly and prolongs the treatment
time. One study [22] showed that 20% of women did not receive
radiotherapy after BCS. It confirmed that age was really the reason
to reduce the number of receiving radiotherapy. Many women under-
going RT to the whole breast may experience pain and discomfort by
acute and chronic skin toxicity. The occurrences of edema and hype
Figure 3. The 5-, 7-year LR-free survival.
Figure 4. The 5-, 7-, and 10-year cancer-specific survival.
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pigmentation usually produce negative emotion. Therefore, recently,
researchers have studied some new methods to reduce the therapeutic
duration time, inconvenience, or toxicity.
The main advantage of ABPI is shortening of the treatment time,
which is appealing especially when radiation resources are limited [21].
However, evidence from randomized trials of the benefits of these
techniques is currently lacking.
In the present meta-analysis, we found that APBI was associated
with a reduction in treatment time and good cosmetic result compared
with WBRT. Our meta-analysis showed the dramatic improvement in
good cosmetic result using breast APBI, and the 5- and 7-year absolute
good cosmetic result was statistically significant compared withWBRT,
APBI being respectively better than WBRT. It produced a significant
25% absolute improvement in good cosmetic results. The 5-, 7-, and
8-year overall survival, recurrence-free survival, cancer-specific survival,
disease-free survival, LR rate, the incidence of contralateral breast
cancer, and distant metastasis rate were not statistically significant.
One study compared that the 10-year overall survival difference was
statistically significant and WBRT was better than the APBI but the
study included small sample size.
APBI is an attractive treatment that needs only 1 to 2 weeks. The
acceleration of RT would eliminate some of the disadvantages of
the extended treatment period, especially for elderly patients. The
rationale for APBI is that the majority of LRs occur in close proximity
to the tumor bed [12,23].
There are some benefits of breast APBI. Partial breast irradiation
did not increase the risk of true recurrence or, elsewhere, breast fail-
ure. Significantly better cosmetic outcome can be achieved compared
Figure 5. The 5- and 10-year disease-free survival.
Figure 6. The 5- and 7-year excellent/good cosmetic results.
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Figure 7. The 5-, 8-, and 10-year LR.
Figure 8. The 5-, 7-, and 10-year contralateral breast cancer.
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with the outcome after WBRT. APBI shortens the period of treat-
ment time in just only 1 to 2 weeks. APBI is only part of the breast
irradiation reducing the target volume and lowering the incidence of
skin toxic.
Due to different ways of radiotherapy, the skin toxicity and cosmetic
results and complications must be concerned. King et al. [24] reported
that the incidence of 1, 2 side effects was 22% using the implanta-
tion radiotherapy, complication rate was 8%, and level 3 (mainly fat
necrosis) required surgery. The other obvious complications that impact
on the cosmetic results were breast fibrosis and telangiectasia [25].
Most of researches [24–26] reported the satisfaction with cosmetic
results more than 90% using APBI treatment.
The present study also had some limitations. First, meta-analysis
based on published data that will overestimate treatment effects and
contained very limited data might interfere with the results of the
present study. Second, between the two treatment arms, the different
RT techniques were allowed, and the statistical power might be
limited for detection of small possible differences in local tumor
control. Third, the quality of all trials included were not high; only
one of the four studies pointed out that randomization was done with
computer-generated method and used a single-blind trial, and the
allocation concealment was clear. One study mentioned the random-
ization method, but blindness and the allocation concealment were all
unclear. Otherwise, only four trials were included in our meta-analysis,
Figure 9. The 5- and 10-year distant metastasis.
Figure 10. The 7-year grade 2 or worse late radiation side effects.
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publication bias was inevitable, and therefore, we did not estimate
publication bias with a funnel plot. So, we should interpret the results
with care, especially for a positive result.
In conclusion, our analysis contained current available evidence
showing that APBI has a better cosmetic result and shortens treatment
time. The overall survival, recurrence-free survival, cancer-specific
survival, disease-free survival, LR rate, the incidence of contralateral
breast cancer, and distant metastasis rate were similar with WBRT.
APBI techniques resulted in a significant reduction of the treatment
time. A future study will focus on treatment time and improving
the quality of life. It will be urgent for large randomized controlled
studies of partial breast radiotherapy to be carried out to validate the
safety and efficacy of these rapidly evolving technologies.
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